Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 results and business highlights released for the three months ended March 31, 2026.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results and business highlights released for the three months ended March 31, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial details and operating updates
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.